Delaying localised prostate cancer treatment ‘does not increase death risk’

According to a new study, active monitoring of the disease has the same high survival rates after 15 years as radiotherapy or surgery.

Delaying localised prostate cancer treatment ‘does not increase death risk’ (Lynne Cameron/PA) (PA Archive)

Delaying treatment for localised prostate cancer does not increase the risk of death, new research suggests.

According to a new study, active monitoring of the disease has the same high survival rates after 15 years as radiotherapy or surgery.

Men on active monitoring – which involves regular tests to check on the cancer – were more likely to see it progress or spread than those receiving radiotherapy or surgery.